PARP inhibitors : clinical relevance and the role of multidisciplinary cancer teams on drug safety
INTRODUCTION: Cancer is considered one of the most devastating causes of death for humanity. Innovative and targeted therapies have become urgent in the treatment of this large subset of diseases. Over the last decade, the development of PARP (poly (ADP-Ribose) polymerase) inhibitors has emerged as a new target in cancer therapy.
AREAS COVERED: The authors conducted a review focusing on the clinic relevance and adverse effects of the four drugs already approved by drug regulatory agencies, namely: olaparib, rucaparib, niraparib and talazoparib. Despite the targeted action of this drug class, the adverse effects should be carefully monitored for the adequate safety of cancer patients taking them. The role of multidisciplinary cancer teams is crucial to help more and more patients to benefit from these revolutionary agents.
EXPERT OPINION: PARP (poly (ADP-Ribose) polymerase) inhibitors are drugs with great potential in the treatment of several types of cancer. However, their toxicity profiles often lead to treatment interruption or early discontinuation. The daily monitoring of these cancer patients by multidisciplinary cancer teams is essential for the success of therapy and for the promotion of a better quality of life.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Expert opinion on drug safety - 21(2022), 4 vom: 12. Apr., Seite 541-551 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jesus, Mafalda [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adverse effects |
|---|
| Anmerkungen: |
Date Completed 22.03.2022 Date Revised 31.05.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14740338.2022.1996561 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332090558 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332090558 | ||
| 003 | DE-627 | ||
| 005 | 20231225214859.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14740338.2022.1996561 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1106.xml |
| 035 | |a (DE-627)NLM332090558 | ||
| 035 | |a (NLM)34668821 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jesus, Mafalda |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PARP inhibitors |b clinical relevance and the role of multidisciplinary cancer teams on drug safety |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.03.2022 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Cancer is considered one of the most devastating causes of death for humanity. Innovative and targeted therapies have become urgent in the treatment of this large subset of diseases. Over the last decade, the development of PARP (poly (ADP-Ribose) polymerase) inhibitors has emerged as a new target in cancer therapy | ||
| 520 | |a AREAS COVERED: The authors conducted a review focusing on the clinic relevance and adverse effects of the four drugs already approved by drug regulatory agencies, namely: olaparib, rucaparib, niraparib and talazoparib. Despite the targeted action of this drug class, the adverse effects should be carefully monitored for the adequate safety of cancer patients taking them. The role of multidisciplinary cancer teams is crucial to help more and more patients to benefit from these revolutionary agents | ||
| 520 | |a EXPERT OPINION: PARP (poly (ADP-Ribose) polymerase) inhibitors are drugs with great potential in the treatment of several types of cancer. However, their toxicity profiles often lead to treatment interruption or early discontinuation. The daily monitoring of these cancer patients by multidisciplinary cancer teams is essential for the success of therapy and for the promotion of a better quality of life | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a PARP inhibitors | |
| 650 | 4 | |a adverse effects | |
| 650 | 4 | |a multidisciplinary cancer teams | |
| 650 | 4 | |a niraparib | |
| 650 | 4 | |a olaparib | |
| 650 | 4 | |a rucaparib | |
| 650 | 4 | |a talazoparib | |
| 650 | 7 | |a Poly(ADP-ribose) Polymerase Inhibitors |2 NLM | |
| 700 | 1 | |a Morgado, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Duarte, Ana Paula |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on drug safety |d 2002 |g 21(2022), 4 vom: 12. Apr., Seite 541-551 |w (DE-627)NLM126588422 |x 1744-764X |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2022 |g number:4 |g day:12 |g month:04 |g pages:541-551 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14740338.2022.1996561 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2022 |e 4 |b 12 |c 04 |h 541-551 | ||